VTRS NASDAQ
Viatris Inc.
1W: +0.2%
1M: +2.6%
3M: +2.4%
YTD: +46.8%
1Y: +79.5%
3Y: +117.7%
5Y: +63.6%
$18.72
+0.43 (+2.35%)
After Hours: $18.76 (+0.04, +0.19%)
Weekly Expected Move ±4.1%
$17
$17
$18
$19
$19
Credit Risk of going bust: lower than 54% of companies Debt: 39.3% of company value Bonds: $302.8M held by 306 funds, 161 bp over Treasuries → details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.76 (down 96%), Viatris Inc. would be worth roughly what it owes.
Total debt $13.63B against a stock market value of $21.01B.
Distance to default 5.55 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $7.55B (short-term plus half of long-term), stock volatility 32.3%; Altman Z 1.13. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $0.76 (down 96%), Viatris Inc. would be worth roughly what it owes.
Total debt $13.63B against a stock market value of $21.01B.
Distance to default 5.55 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $7.55B (short-term plus half of long-term), stock volatility 32.3%; Altman Z 1.13. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (24h)
1
Hourly Sentiment (24h)
0.60
Bullish
2 bullish
1 neutral
0 bearish
Articles (7d)
3
Daily Sentiment (7 Days)
Articles (100)
Will Viatris (VTRS) Beat Estimates Again in Its Next Earnings Report?
Why Viatris (VTRS) is a Top Momentum Stock for the Long-Term
Notable healthcare headlines for the week: Moderna, Roche, and Abbott Laboratories in focus
Here's Why Viatris (VTRS) is a Strong Value Stock
Viatris, Opus granted FDA label expansion for Ryzumvi in presbyopia
SA analyst upgrades/downgrades: META, VTRS, MRVL, COKE
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio
Why Pacira BioSciences Skyrocketed Today
4 stocks to watch on Thursday: AVGO, PLTR, AMZN, and VTRS
Viatris to buy Pacira BioSciences for $36.50/share in cash
VTRS vs. AVTR: Which Stock Is the Better Value Option?
Should Value Investors Buy Viatris (VTRS) Stock?
Viatris (VTRS) is a Top-Ranked Momentum Stock: Should You Buy?
Stock index futures tick higher ahead of jobs report
Why Viatris (VTRS) is a Top Value Stock for the Long-Term
Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year
Viatris sues Novo Nordisk, seeks to market generic Wegovy
Trump seeks to produce more generic drugs in the US
Viatris, Teva initiated at Outperform at Oppenheimer
Looming biosimilar void risks $189B in lost U.S. healthcare savings: report
Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy?
Healthcare August recap: Moderna jumps 156% as biotech shines; DaVita sinks
Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and Viatris
3 Generic Drug Stocks to Watch Amid Improving Industry Trends
Here's Why Viatris (VTRS) is a Strong Value Stock
Viatris Inc. stock rises Friday, outperforms market - MarketWatch
Viatris (VTRS) Q2 2026 Earnings Call Transcript
Viatris Inc. stock falls Wednesday, underperforms market - MarketWatch
Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks
Notable healthcare headlines for the week: Eli Lilly, Novo Nordisk, and Pfizer in focus
Viatris Inc. stock falls Thursday, underperforms market - MarketWatch
VTRS Q2 Earnings Beat, Revenues Rise 5% as Greater China Sales Jump
Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics
Viatris (VTRS) Beats Q2 Earnings and Revenue Estimates
Viatris Non-GAAP EPS of $0.69 beats by $0.09, revenue of $3.75B beats by $80M
Viatris (VTRS) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
CVS Health (CVS) Q2 Earnings and Revenues Beat Estimates
Viatris Gears Up to Report Q2 Earnings: What's in the Cards?
GeneDx Holdings Corp. (WGS) Q2 Earnings and Revenues Surpass Estimates
Earnings Week Ahead: PLTR, AMD, PFE, DIS, SHOP, VTRS, CGC, MCD, ROKU, ABNB, and more
Earnings scorecard: eight out of nine healthcare companies deliver EPS wins this week
Earnings Scoreboard: 84% of S&P 500 reporting firms top EPS estimates as 72% post Y/Y profit growth
July healthcare recap: Regeneron, DexCom shine as Moderna, managed-care stocks retreat
Viatris (VTRS) Q2 Earnings Preview: What's in the Cards?
Most S&P 500 stocks trade above 50-day moving average for first time since February
Stock index futures edge higher as investors seek rebound after Thursday selloff
Trump outlines plans for up to 200% tariffs on generic drug imports starting in 2028
Why Viatris (VTRS) is a Top Value Stock for the Long-Term
VTRS or DHR: Which Is the Better Value Stock Right Now?
Should Value Investors Buy Viatris (VTRS) Stock?
Viatris (VTRS) is a Great Momentum Stock: Should You Buy?
Theravance Stock Down 3% After Zymeworks Announces Buyout
Viatris reports positive Japanese phase 3 results for Nefecon in IgAN
Here's Why Viatris (VTRS) is a Strong Momentum Stock
Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy?
VTRS vs. DHR: Which Stock Is the Better Value Option?
Are Investors Undervaluing Viatris (VTRS) Right Now?
Here's Why You Should Add LXRX Stock to Your Portfolio Now
Notable healthcare headlines for the week: Merck, Moderna, and Biogen in focus
Is Amneal a Buy Before Rytary Generic Erosion?
3 Generic Drug Stocks to Watch as New Growth Drivers Emerge
Here's Why Viatris (VTRS) is a Strong Value Stock
Viatris Inc. stock rises Friday, outperforms market - MarketWatch
FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy
Here's Why Viatris (VTRS) is a Strong Momentum Stock
Why Viatris (VTRS) is a Top Value Stock for the Long-Term
Why Viatris (VTRS) is a Top Growth Stock for the Long-Term
Most healthcare companies report higher Y/Y EPS in strong earnings week
RFK Jr. Wants Fewer Americans On Antidepressants — Here's Why The Debate Is Exploding
TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline Hurdle
Viatris Inc. stock rises Thursday, outperforms market - MarketWatch
Viatris Inc. stock rises Thursday, outperforms market - MarketWatch
Viatris (VTRS) Q1 2026 Earnings Transcript
Viatris signals 2026 cash deployment of more than $2.5B while expecting Greater China mid- to high-single-digit growth
Viatris Q1 EPS Beats Estimates, Revenues up 8% Driven by Greater China
Here's What Key Metrics Tell Us About Viatris (VTRS) Q1 Earnings
Viatris rises as Q1 beat indicates growth momentum
Viatris (VTRS) Q1 Earnings and Revenues Surpass Estimates
Viatris Non-GAAP EPS of $0.59 beats by $0.09, revenue of $3.51B beats by $150M
Viatris Q1 2026 Earnings Preview: Caution remains around ongoing turnaround
Exploring Analyst Estimates for Viatris (VTRS) Q1 Earnings, Beyond Revenue and EPS
Viatris Gears Up to Report Q1 Earnings: What's in the Cards?
Stock index futures rise ahead of economic reports
Viatris Announces Chief Financial Officer Transition
Stock index futures mixed as focus remains on U.S.-Iran developments
Healthcare earnings impress with 86% beat rate, yet sector lags: Earnings Scorecard
Viatris (VTRS) Earnings Expected to Grow: Should You Buy?
Notable healthcare headlines for the week: J&J, Abbott and Organon in focus
Viatris Inc. stock rises Friday, outperforms market - MarketWatch
QSM Asset Management Loads Up 611,000 Mobileye Shares
The 10 Healthcare stocks with the lowest forward P/E ratios
Theravance Stock Declines Around 17% in Three Months: Here's Why
AMRX: 3 Growth Drivers Behind Amneal's 2026 Outlook
Is AMRX Stock Undervalued? Sales Multiple, Target, Upside
Here's How AMRX Is Tapping GLP-1 Demand Through Manufacturing
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Insider trades: CrowdStrike, Palo Alto, Lululemon among notable names
Citi's top large-cap stocks with positive ROE trends
Theravance's Q4 Earnings and Revenues Miss Estimates